OPA Looking More Closely at Drug Manufacturer 340B Compliance

by Admin | September 26, 2012 9:30 am

September 26, 2012—After a year of unprecedented scrutiny of 340B covered entities, there are signs the Office of Pharmacy Affairs (OPA) is beginning to look more closely at whether drug manufacturers are fulfilling their obligations under the drug discount program and might even begin auditing some companies.

OPA is “in the process of looking into some issues” with drug manufacturers’ 340B pricing, the office’s director, Cmdr. Krista Pedley, said on Sept. 11 at a major pharmaceutical pricing conference in Chicago. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2012/09/opa-looking-more-closely-at-drug-manufacturer-340b-compliance/

---